Pharmacyclics (Seller)AbbVie (Buyer)
AbbVie will acquire Pharmacyclics for $261.25 per share in cash and stock, or about $21 billion
Pharmacyclics (Licensor)Servier (Licensee)
Pharmacyclics granted Servier exclusive, worldwide rights to to develop and commercialize PCI-24781, excluding the U.S.
Set Email Alert